Skip to main content

ADME SARfari: A tool for predicting and comparing cross-species ADME targets






ADME studies are focused on understanding the disposition of a compound within an organism and the results of such studies play a critical role in the drug development process. ADME studies (more commonly referred to as pharmacokinetic or PK studies) are focused on 4 main areas: Absorption, Distribution, Metabolism and Excretion. More information on the PK measurement types can be found here.

Comparisons of PK data across species is a potential problem drug researchers need to deal with, as model organism studies are the primary source of such data. For example, in an animal model study, which may be carried out on a compound as it passes through the drug development pipeline, is it meaningful to compare clearance or bioavailability data from a mouse or rat to human? Clearly there are many differences (physical, metabolic, genetic,..), which make answering these types of questions difficult. Building tools which guide researchers to potential answers or provide a better understanding of the inter-species differences are of great value - leading us nicely to the focus of this blog post.

https://www.ebi.ac.uk/chembl/admesarfari


It turns out the ChEMBL database has a wealth of PK measurements data, which allows users to start asking ADME focused questions. You can access all of this data via the ChEMBL Interface or from one of our downloads, but in order to answer some of the more complex questions a significant amount of data processing first needs to take place. So to help the ChEMBL community get started analysing this data, we, in collaboration with our colleagues at GSK, set about building a new ADME focused system. The new system is called ADME SARfari and it aims to centralise all ADME data currently stored in ChEMBL and other related databases, as well as providing new tools to help interrogate the data.


In order to build the system we have pulled data from a number of sources, which include:
  • ChEMBL - Bioactivity data, PK data and molecules.
  • PharmaADME - An online resource providing a list ADME related human genes. We used this to build our primary list of ADME Targets, but have also added a couple of extra ones.
  • The Human Protein Atlas -  Protein expression data for human ADME Targets.
  • ENSEMBL - Orthologue (using the Compara Service) and SNP data for ADME Targets.
  • The Göttingen minipig and beagle dog genome predicted ADME Targets. GSK have sequenced the  genomes of these two pharmaceutically significant species. More details on the genomes can be found here.
When you visit the site you will find it is divided into the following 7 sections:
  • Home - Allows user to initiate a compound or protein focused search.
  • Orthologues - A table of ADME orthologues. The first column of the table corresponds to the human ADME targets and additional columns correspond to targets found in model organisms.
  • Tissues - Protein expression data for human ADME targets.
  • Bioactivities - Bioactivity data and PK measurements for all ADME related targets in the system, which are also found in the ChEMBL database.
  • Molecules - Distinct set of ChEMBL molecules linked to ADME related targets via the bioactivity data.
  • Pharmacokinetic - A cross species comparison of PK data for compounds found in the  ChEMBL database  (see red heatmap image at top).
  • About - More details on how to use the system
By clicking on the links above, you can view and download all of the data associated within each of the sections. One exception is the Pharmacokinetics section, as there is too much data to display in the heatmap by default, so you must first initiate a search (we will come back to this later). Now that you have a better idea of what is in the system, what are the types of questions you can ask? Looking at the homepage you will see there are 2 ways to initiate a search of the system: Compound-initiated, using the chemical sketcher box and protein-initiated, using the BLAST or keyword search.


Protein Search  (Using BLAST)

To run a BLAST search paste a sequence in the text box to the right on the homepage:



BLAST search results will be displayed on the Orthologues page and only rows which contain hits to your search query will be returned:





Clicking on the Tissues tab displays the protein expression levels of the human targets returned by the BLAST search:




Clicking on the Bioactivities tab returns all of the ChEMBL bioactivity data for targets returned by BLAST search:




Clicking on the Molecules tab returns the distinct set of compounds currently displayed in the Bioactivities section:



Clicking on the Pharmacokinetics tab will provide a cross-species overview of the PK data in ChEMBL for the compounds currently displayed in the Molecules section (Note that not all compounds will have PK measurements):




The following points help explain what the heatmap above is displaying:
  • Each narrow row corresponds to a compound.
  • Each column corresponds to a PK measurement in a specific organism. 
  • The PK measurements summarised in this view are Clearance (Cl), Cmax, Bioavailability (f), T1/2, Tmax and Volume of Distribution (Vd). 
  • The colour of each cell corresponds to a low, medium and high binned PK measurement, making it easier to compare values across species.
  • The columns can be sorted by clicking on the header (see the second column, which corresponds to the Human Clearance data).

Compound Search

It is also possible to search the system using a compound structure. Simply draw or paste a structure into the compound sketcher on the left of the homepage:

 

You can then choose to run a substructure and similarity search. When you run the search you will first be taken Molecules section and you can then explore the other sections, which are all connected based on this initial set of compounds.


Predictive Model Search

The system also allows a user to predict which ADME protein target a molecule will interact with. The binding data (displayed in the Bioactivities section) has been used to build a multi-category naive Bayesian  classifier. We will follow up with a more detailed post describing the model building process, but essentially the model is able to predict if a user-submitted molecule will interact with 133 of the ADME targets included in the system. The About page provides some additional data on the targets included in the model. 

To run a search against the predictive model, draw or paste a structure into the compound sketcher on the left of the homepage and hit the "Model Prediction" button. You will be taken to the Orthologues section, but only the rows which include a target predicted to interact with submitted molecule (coloured green) will be on display:





We hope you find the ADME SARfari system useful and if you have any questions please let us know.

The ChEMBL Team

Comments

Popular posts from this blog

ChEMBL 34 is out!

We are delighted to announce the release of ChEMBL 34, which includes a full update to drug and clinical candidate drug data. This version of the database, prepared on 28/03/2024 contains:         2,431,025 compounds (of which 2,409,270 have mol files)         3,106,257 compound records (non-unique compounds)         20,772,701 activities         1,644,390 assays         15,598 targets         89,892 documents Data can be downloaded from the ChEMBL FTP site:  https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/ Please see ChEMBL_34 release notes for full details of all changes in this release:  https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/chembl_34_release_notes.txt New Data Sources European Medicines Agency (src_id = 66): European Medicines Agency's data correspond to EMA drugs prior to 20 January 2023 (excluding vaccines). 71 out of the 882 newly added EMA drugs are only authorised by EMA, rather than from other regulatory bodies e.g.

New SureChEMBL announcement

(Generated with DALL-E 3 ∙ 30 October 2023 at 1:48 pm) We have some very exciting news to report: the new SureChEMBL is now available! Hooray! What is SureChEMBL, you may ask. Good question! In our portfolio of chemical biology services, alongside our established database of bioactivity data for drug-like molecules ChEMBL , our dictionary of annotated small molecule entities ChEBI , and our compound cross-referencing system UniChem , we also deliver a database of annotated patents! Almost 10 years ago , EMBL-EBI acquired the SureChem system of chemically annotated patents and made this freely accessible in the public domain as SureChEMBL. Since then, our team has continued to maintain and deliver SureChEMBL. However, this has become increasingly challenging due to the complexities of the underlying codebase. We were awarded a Wellcome Trust grant in 2021 to completely overhaul SureChEMBL, with a new UI, backend infrastructure, and new f

Accessing SureChEMBL data in bulk

It is the peak of the summer (at least in this hemisphere) and many of our readers/users will be on holiday, perhaps on an island enjoying the sea. Luckily, for the rest of us there is still the 'sea' of SureChEMBL data that awaits to be enjoyed and explored for hidden 'treasures' (let me know if I pushed this analogy too far). See here and  here for a reminder of SureChEMBL is and what it does.  This wealth of (big) data can be accessed via the SureChEMBL interface , where users can submit quite sophisticated and granular queries by combining: i) Lucene fields against full-text and bibliographic metadata and ii) advanced structure query features against the annotated compound corpus. Examples of such queries will be the topic of a future post. Once the search results are back, users can browse through and export the chemistry from the patent(s) of interest. In addition to this functionality, we've been receiving user requests for  local (behind the

New Drug Approvals - Pt. XVII - Telavancin (Vibativ)

The latest new drug approval, on 11th September 2009 was Telavancin - which was approved for the treatment of adults with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria , including Staphylococcus aureus , both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains. Telavancin is also active against Streptococcus pyogenes , Streptococcus agalactiae , Streptococcus anginosus group (includes S. anginosus, S. intermedius and S. constellatus ) and Enterococcus faecalis (vancomycin susceptible isolates only). Telavancin is a semisynthetic derivative of Vancomycin. Vancomycin itself is a natural product drug, isolated originally from soil samples in Borneo, and is produced by controlled fermentation of Amycolatopsis orientalis - a member of the Actinobacteria . Telavancin has a dual mechanism of action, firstly it inhibits bacterial cell wall synthesis by interfering with the polymerization and cross-linking of peptid

A python client for accessing ChEMBL web services

Motivation The CheMBL Web Services provide simple reliable programmatic access to the data stored in ChEMBL database. RESTful API approaches are quite easy to master in most languages but still require writing a few lines of code. Additionally, it can be a challenging task to write a nontrivial application using REST without any examples. These factors were the motivation for us to write a small client library for accessing web services from Python. Why Python? We choose this language because Python has become extremely popular (and still growing in use) in scientific applications; there are several Open Source chemical toolkits available in this language, and so the wealth of ChEMBL resources and functionality of those toolkits can be easily combined. Moreover, Python is a very web-friendly language and we wanted to show how easy complex resource acquisition can be expressed in Python. Reinventing the wheel? There are already some libraries providing access to ChEMBL d